Bristol-Myers Squibb - שווי פירמה כולל BMY
The economic moat of Bristol-Myers Squibb (BMY) is currently under threat due to the expiration of several patents, which is temporarily compressing margins. The linear price action on the GURU.Markets platform chart shows an Enterprise Value of 159857.81. The business relies on steady demand in cardiology and oncology, generating a solid free cash flow. Additionally, the corporation is developing cell therapy through strategic alliances and licenses with innovative startups.
פילוחי נתונים אנליטיים מרוכזים עבור Bristol-Myers Squibb (BMY)
The stability of Bristol-Myers Squibb (BMY) is based on the high margins of proprietary biopharmaceutical drugs for the therapy of critical diseases. By summing market capitalization with net debt, enterprise value levels determine the actual cost of acquiring the entire business, allowing an investor to assess the real price of the asset stripped of market noise and emotional price fluctuations.